口服抗生素与静脉联合口服抗生素治疗非复杂性急性阑尾炎的三年结局:APPAC II随机临床试验的二次分析
该研究为APPAC II非劣效性多中心随机临床试验的预设3年随访二次分析,比较口服莫西沙星单药与静脉厄他培南联合口服左氧氟沙星和甲硝唑治疗CT证实的非复杂性急性阑尾炎。3年治疗成功率口服组63.4% vs 联合组65.2%,差异-1.8个百分点(单侧95%CI -8.3至∞;非劣效性P=0.14),置信区间上限超过非劣效界值,未能证明口服单药非劣效。两组治疗相关不良事件、生活质量、住院时间和病假时长无显著差异。
要点
- 3年治疗成功率口服抗生素单药组63.4%,静脉联合口服抗生素组65.2%。
- 两组成功率差异-1.8个百分点(单侧95%CI -8.3至∞),非劣效性未成立。
- 两组治疗相关不良事件、生活质量、住院时间和病假时长无显著差异。
核心结论
- 口服抗生素单药组阑尾切除率略高,但未能证明其相对于静脉联合口服抗生素的非劣效性;结果鼓励未来研究评估口服单药作为非复杂性急性阑尾炎的可行替代治疗。
研究设计与样本
- APPAC II非劣效性多中心随机临床试验的预设3年随访二次分析,在芬兰9所大学和中心医院于2017年4月至2018年11月开展,末次随访为2022年11月。
- 纳入18至60岁患者,随机接受口服抗生素单药(n=301)或静脉联合口服抗生素(n=298);排除后599例被随机分组(平均[SD]年龄36[12]岁;男性336例[56.1%]),退出和失访后582例(99.8%)可进行3年随访分析。
主要发现
- 3年治疗成功率口服抗生素单药组为63.4%(单侧95%CI 58.8%至∞),静脉联合口服抗生素组为65.2%(单侧95%CI 60.5%至∞)。
- 两组3年治疗成功率差异为-1.8个百分点(单侧95%CI -8.3个百分点至∞;非劣效性P=0.14),置信区间上限超过非劣效界值。
- 两组在治疗相关不良事件、生活质量、住院时间和病假时长方面无显著差异。
关键数值与推荐
- 口服抗生素单药方案为口服莫西沙星400 mg/d,共7天。
- 静脉联合口服抗生素方案为静脉厄他培南钠1 g/d共2天,加上口服左氧氟沙星500 mg/d和甲硝唑500 mg每日3次共5天。
- 主要终点为治疗成功,定义为急性阑尾炎缓解且无需手术干预出院、3年随访时无阑尾炎复发,采用非劣效性设计评价。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Current short-term evidence has shown that uncomplicated acute appendicitis can be treated successfully with oral antibiotics alone, but longer-term results are lacking. OBJECTIVE: To assess the treatment effectiveness of oral antibiotic monotherapy compared with combined intravenous (IV) and oral antibiotics in computed tomography-confirmed uncomplicated acute appendicitis at a longer-term follow-up. DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of a predefined year 3 follow-up of the Appendicitis Acuta II (APPAC II) noninferiority, multicenter randomized clinical trial compared oral moxifloxacin with combined IV ertapenem plus oral levofloxacin and metronidazole for the treatment of uncomplicated acute appendicitis. The trial was conducted at 9 university and central hospitals in Finland from April 2017 to November 2018, with the last follow-up in November 2022. Participants included patients aged 18 to 60 years, who were randomized to receive either oral antibiotics monotherapy (n = 301) or combined IV and oral antibiotics (n = 298). INTERVENTIONS: Antibiotics monotherapy consisted of oral moxifloxacin, 400 mg/d, for 7 days. Combined IV and oral antibiotics consisted of IV ertapenem sodium, 1 g/d, for 2 days plus oral levofloxacin, 500 mg/d, and metronidazole, 500 mg 3 times/d, for 5 days. MAIN OUTCOMES AND MEASURES: The primary end point was treatment success, defined as the resolution of acute appendicitis and discharge from hospital without the need for surgical intervention and no appendicitis recurrence at the year 3 follow-up evaluated using a noninferiority design. The secondary end points included late (after 1 year) appendicitis recurrence as well as treatment-related adverse events, quality of life, length of hospital stay, and length of sick leave, which were evaluated using a superiority design. RESULTS: After exclusions, 599 patients (mean [SD] age, 36 [12] years; 336 males [56.1%]) were randomized; after withdrawal and loss to follow-up, 582 patients (99.8%) were available for the year 3 follow-up. The treatment success at year 3 was 63.4% (1-sided 95% CI, 58.8% to ∞) in the oral antibiotic monotherapy group and 65.2% (1-sided 95% CI, 60.5% to ∞) in the combined IV and oral antibiotics group. The difference in treatment success rate between the groups at year 3 was -1.8 percentage points (1-sided 95% CI, -8.3 percentage points to ∞; P = .14 for noninferiority), with the CI limit exceeding the noninferiority margin. There were no significant differences between groups in treatment-related adverse events, quality of life, length of hospital stay, or length of sick leave. CONCLUSIONS AND RELEVANCE: This secondary analysis of the APPAC II trial found a slightly higher appendectomy rate in patients who received oral antibiotic monotherapy; however, noninferiority of oral antibiotic monotherapy compared with combined IV and oral antibiotics could not be demonstrated. The results encourage future studies to assess oral antibiotic monotherapy as a viable treatment alternative for uncomplicated acute appendicitis. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03236961.
引用
- Selänne L, Haijanen J, Sippola S, et al. Three-Year Outcomes of Oral Antibiotics vs Intravenous and Oral Antibiotics for Uncomplicated Acute Appendicitis: A Secondary Analysis of the APPAC II Randomized Clinical Trial. JAMA Surg. 2024. PMID: 38630471. doi:10.1001/jamasurg.2023.5947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。